RANIA, NCT02116660 / 2013-001637-40: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) |
|
|
| Terminated | 2 | 11 | NA | Raltegravir (MK-0518), Nevirapine, Lamivudine, Tenofovir, Emtricitabine, Lopinavir, Ritonavir, Atazanavir, Darunavir | Merck Sharp & Dohme LLC | HIV Infections | 07/17 | 07/17 | | |